Compare · NTHI vs NVO
NTHI vs NVO
Side-by-side comparison of NeOnc Technologies Holdings Inc. (NTHI) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTHI and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 1763.8x NTHI ($122.2M).
- NTHI has been more active in the news (26 items in the past 4 weeks vs 9 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 3 for NTHI).
- Company
- NeOnc Technologies Holdings Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $122.2M
- $215.46B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 26
- 9
- Recent ratings
- 3
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NTHI
- Amendment: NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Leadership Update
- CEO Chen Thomas C bought $69,998 worth of shares (12,757 units at $5.49) (SEC Form 4)
- Amendment: Chief Scientific Officer Chen Thomas C bought $192,899 worth of shares (47,207 units at $4.09), increasing direct ownership by 7% to 583,531 units (SEC Form 4)
- NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- CEO Chen Thomas C bought $140,000 worth of shares (36,259 units at $3.86), increasing direct ownership by 7% to 583,531 units (SEC Form 4)
- CEO, President Heshmatpour Amir F bought $49,860 worth of shares (9,000 units at $5.54), increasing direct ownership by 0.29% to 3,096,000 units (SEC Form 4)
- NeOnc Technologies- Talk Is Cheap, Insider Buying Isn’t
- CEO, President Heshmatpour Amir F bought $58,580 worth of shares (15,000 units at $3.91), increasing direct ownership by 0.49% to 3,087,000 units (SEC Form 4)
- These Nasdaq Stories Are Heating Up
- NTHI’s Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S